Seer, Inc. (SEER)
NASDAQ: SEER · Real-Time Price · USD
1.675
-0.005 (-0.30%)
Apr 1, 2026, 3:09 PM EDT - Market open
Seer, Inc. Revenue
In the year 2025, Seer, Inc. had annual revenue of $16.58M with 16.99% growth. Seer, Inc. had revenue of $4.20M in the quarter ending December 31, 2025, with 5.03% growth.
Revenue (ttm)
$16.58M
Revenue Growth
+16.99%
P/S Ratio
5.72
Revenue / Employee
$133,694
Employees
124
Market Cap
94.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.58M | 2.41M | 16.99% |
| Dec 31, 2024 | 14.17M | -2.49M | -14.95% |
| Dec 31, 2023 | 16.66M | 1.17M | 7.54% |
| Dec 31, 2022 | 15.49M | 8.88M | 134.14% |
| Dec 31, 2021 | 6.62M | 5.96M | 908.69% |
| Dec 31, 2020 | 656.00K | 540.00K | 465.52% |
| Dec 31, 2019 | 116.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 62.30M |
| Q32 Bio | 53.74M |
| Sangamo Therapeutics | 39.55M |
| Verrica Pharmaceuticals | 35.58M |
| Pyxis Oncology | 13.86M |
| Coya Therapeutics | 7.95M |
| Spruce Biosciences | 697.00K |
SEER News
- 2 days ago - Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries - GlobeNewsWire
- 4 weeks ago - The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs - Business Wire
- 4 weeks ago - Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets - GlobeNewsWire
- 4 weeks ago - Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook - GlobeNewsWire
- 5 weeks ago - The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change - Business Wire
- 5 weeks ago - Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026 - GlobeNewsWire
- 5 weeks ago - Seer to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire